$MSSA
Metal Sky Star Acquisition Corp Stock $mssa

$mssa Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000149315224036959 Filed on September 18, 2024

Income Statement

Concept	2024 Q1	2023 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$161.8K	$263.4K
YoY Change	-38.57%	7320.28%
Operating Profit		-$263.4K
YoY Change		7320.23%
Interest Expense	$458.8K	$858.9K
YoY Change	-46.58%
% of Operating Profit
Other Income/Expense, Net	$458.8K	$858.9K
YoY Change	-46.58%
Pretax Income	$297.0K	$595.5K
YoY Change	-50.12%	-16874.7%
Income Tax
% Of Pretax Income
Net Earnings	$297.0K	$595.5K
YoY Change	-50.12%	-16874.7%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.05	$0.07
COMMON SHARES
Basic Shares Outstanding	6.407M shares	8.820M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments		$58.20M
YoY Change
Cash & Equivalents	$0.00	$0.00
Short-Term Investments		$58.20M
Other Short-Term Assets		$133.2K
YoY Change		-67.64%
Inventory
Prepaid Expenses	$600.00
Receivables
Other Receivables
Total Short-Term Assets	$600.00	$58.33M
YoY Change	-100.0%	14071.15%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$36.07M	-$1.00
YoY Change	-3606792800.0%
TOTAL ASSETS
Total Short-Term Assets	$600.00	$58.33M
Total Long-Term Assets	$36.07M	-$1.00
Total Assets	$36.07M	$58.33M
YoY Change	-38.17%	14071.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$404.8K	$289.1K
YoY Change	40.01%	151.34%
Deferred Revenue
YoY Change
Short-Term Debt		$793.6K
YoY Change		164.52%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.257M	$3.958M
YoY Change	-17.7%	853.57%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$2.875M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.257M	$3.958M
Total Long-Term Liabilities	$2.875M	$0.00
Total Liabilities	$6.132M	$3.958M
YoY Change	54.94%	853.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$6.085M	-$3.828M
YoY Change	58.96%
Common Stock	$3.205K	$3.205K
YoY Change	0.0%	11.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.081M	-$3.824M
YoY Change
Total Liabilities & Shareholders Equity	$36.07M	$58.33M
YoY Change	-38.17%	14071.15%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$297.0K	$595.5K
YoY Change	-50.12%	-16874.7%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$82.16K
YoY Change		96.32%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$250.0K	$59.33M
YoY Change	-100.42%
Cash From Investing Activities	-$250.0K	$59.33M
YoY Change	-100.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$250.0K	-$59.30M
YoY Change	-100.42%
NET CHANGE
Cash From Operating Activities		-$82.16K
Cash From Investing Activities	-$250.0K	$59.33M
Cash From Financing Activities	$250.0K	-$59.30M
Net Change In Cash		-$46.28K
YoY Change		10.59%
FREE CASH FLOW
Cash From Operating Activities		-$82.16K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
CY2024Q1	MSSA	Cash Withdrawn From Trust Account To Redeem Public Shares CashWithdrawnFromTrustAccountToRedeemPublicShares		usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2024Q1	us-gaap	Escrow Deposit EscrowDeposit		usd
CY2023Q4	us-gaap	Escrow Deposit EscrowDeposit		usd
CY2024Q1	us-gaap	Cash Cash		usd
CY2024Q1	us-gaap	Escrow Deposit EscrowDeposit		usd
CY2023Q4	us-gaap	Escrow Deposit EscrowDeposit		usd
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	600	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1875	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	600	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1875	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	35359088	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	36067927	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	35359088	usd
CY2024Q1	us-gaap	Assets Assets	36068527	usd
CY2023Q4	us-gaap	Assets Assets	35360963	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	404824	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	375834	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	2422403	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2172403	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3257061	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2846517	usd
CY2024Q1	MSSA	Deferred Underwriting Commissions DeferredUnderwritingCommissions	2875000	usd
CY2023Q4	MSSA	Deferred Underwriting Commissions DeferredUnderwritingCommissions	2875000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2875000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2875000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	6132061	usd
CY2023Q4	us-gaap	Liabilities Liabilities	5721517	usd
CY2024Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3202416	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11500000	shares
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	36017927	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	35409088	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3205000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3205000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	3205	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6084666	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5772847	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-6081461	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36068527	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35360963	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
CY2023Q1	MSSA	Increase Decrease In Due To Sponsor IncreaseDecreaseInDueToSponsor		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities		usd
CY2024Q1	MSSA	Cash Withdrawn From Trust Account To Redeem Public Shares CashWithdrawnFromTrustAccountToRedeemPublicShares		usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect		usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2024Q1	us-gaap	Escrow Deposit EscrowDeposit		usd
CY2023Q4	us-gaap	Escrow Deposit EscrowDeposit		usd
CY2024Q1	us-gaap	Cash Cash		usd
CY2024Q1	us-gaap	Escrow Deposit EscrowDeposit		usd
CY2023Q4	us-gaap	Escrow Deposit EscrowDeposit		usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	600	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1875	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	600	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1875	usd
CY2024Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	36067927	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	35359088	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	36067927	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	35359088	usd
CY2024Q1	us-gaap	Assets Assets	36068527	usd
CY2023Q4	us-gaap	Assets Assets	35360963	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	404824	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	298280	usd
CY2024Q1	us-gaap	Other Liabilities OtherLiabilities	429834	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	375834	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	2422403	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2172403	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3257061	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2846517	usd
CY2023Q4	MSSA	Deferred Underwriting Commissions DeferredUnderwritingCommissions	2875000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2875000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2875000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	6132061	usd
CY2023Q4	us-gaap	Liabilities Liabilities	5721517	usd
CY2024Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3202416	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11500000	shares
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	36017927	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	35409088	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3205000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3205000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3205000	shares
CY2024Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3202416	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11500000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	3205	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3205	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5772847	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-6081461	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5769642	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36068527	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35360963	usd
CY2024Q1	MSSA	Formation And Operational Costs FormationAndOperationalCosts	161819	usd
CY2023Q1	MSSA	Formation And Operational Costs FormationAndOperationalCosts	263418	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	161819	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	263418	usd
CY2024Q1	us-gaap	Interest Income Operating InterestIncomeOperating	301779	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	636054	usd
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	157060	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	458839	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	297020	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	595502	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	297020	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	595502	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5769642	usd
CY2024Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Additional Funding For Business Combination Extension SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionAdditionalFundingForBusinessCombinationExtension	-150000	usd
CY2024Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount	-458839	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	297020	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2803403	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2803403	usd
CY2023Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Additional Funding For Business Combination Extension SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionAdditionalFundingForBusinessCombinationExtension	-757676	usd
CY2023Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount	-858920	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	595502	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3824497	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3824497	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	297020	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	595502	usd
CY2024Q1	us-gaap	Interest Income Operating InterestIncomeOperating	301779	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	636054	usd
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	157060	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	222866	usd
CY2024Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1875	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	38861	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	600	usd
CY2024Q1	MSSA	Increase Decrease In Due To Sponsor IncreaseDecreaseInDueToSponsor	54000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	106544	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	142398	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	250000	usd
CY2024Q1	MSSA	Formation And Operational Costs FormationAndOperationalCosts	161819	usd
CY2023Q1	MSSA	Formation And Operational Costs FormationAndOperationalCosts	263418	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	161819	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	263418	usd
CY2024Q1	us-gaap	Interest Income Operating InterestIncomeOperating	301779	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	636054	usd
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	157060	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	222866	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	458839	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	858920	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	297020	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	595502	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	297020	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	595502	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5769642	usd
CY2024Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Additional Funding For Business Combination Extension SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionAdditionalFundingForBusinessCombinationExtension	-150000	usd
CY2024Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount	-458839	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	297020	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-6081461	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2803403	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2803403	usd
CY2023Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Additional Funding For Business Combination Extension SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionAdditionalFundingForBusinessCombinationExtension	-757676	usd
CY2023Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned On Trust Account SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedOnTrustAccount	-858920	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3824497	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	595502	usd
CY2024Q1	us-gaap	Interest Income Operating InterestIncomeOperating	301779	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	636054	usd
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	157060	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	222866	usd
CY2024Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1875	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	38861	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	600	usd
CY2024Q1	MSSA	Increase Decrease In Due To Sponsor IncreaseDecreaseInDueToSponsor	54000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	106544	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	142398	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82159	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	250000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	757676	usd
CY2023Q1	MSSA	Cash Withdrawn From Trust Account To Redeem Public Shares CashWithdrawnFromTrustAccountToRedeemPublicShares	60089158	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	59331482	usd
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	793551	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	60089158	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	250000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-59295607	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-46284	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	178652	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	132368	usd
CY2024Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned Unrealized Gain On Trust Account And Additional Funding For Business Combination Extension SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedUnrealizedGainOnTrustAccountAndAdditionalFundingForBusinessCombinationExtension	608839	usd
CY2023Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned Unrealized Gain On Trust Account And Additional Funding For Business Combination Extension SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedUnrealizedGainOnTrustAccountAndAdditionalFundingForBusinessCombinationExtension	1616596	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	757676	usd
CY2023Q1	MSSA	Cash Withdrawn From Trust Account To Redeem Public Shares CashWithdrawnFromTrustAccountToRedeemPublicShares	60089158	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-250000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	59331482	usd
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	793551	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	60089158	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	250000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-59295607	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	178652	usd
CY2024Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned Unrealized Gain On Trust Account And Additional Funding For Business Combination Extension SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedUnrealizedGainOnTrustAccountAndAdditionalFundingForBusinessCombinationExtension	608839	usd
CY2023Q1	MSSA	Subsequent Measurement Of Ordinary Shares Subject To Redemption Interest Earned Unrealized Gain On Trust Account And Additional Funding For Business Combination Extension SubsequentMeasurementOfOrdinarySharesSubjectToRedemptionInterestEarnedUnrealizedGainOnTrustAccountAndAdditionalFundingForBusinessCombinationExtension	1616596	usd
CY2022Q2	MSSA	Proceeds From Ipo And Private Placement ProceedsFromIpoAndPrivatePlacement	115682250	usd
CY2024Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	36067927	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	35359088	usd
CY2022Q2	MSSA	Proceeds From Ipo And Private Placement ProceedsFromIpoAndPrivatePlacement	115682250	usd
CY2024Q1	MSSA	Working Capital Deficit WorkingCapitalDeficit	-3256461	usd
CY2023Q4	MSSA	Working Capital Deficit WorkingCapitalDeficit	-2844642	usd
CY2024Q1	MSSA	Working Capital Deficit WorkingCapitalDeficit	-3256461	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zEImzqO6Y2U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zzsrUlA4zC4g">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	MSSA	Proceeds From Ipo And Private Placement ProceedsFromIpoAndPrivatePlacement	115682250	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	35359088	usd
CY2024Q1	MSSA	Working Capital Deficit WorkingCapitalDeficit	-3256461	usd
CY2023Q4	MSSA	Working Capital Deficit WorkingCapitalDeficit	-2844642	usd
CY2024Q1	MSSA	Working Capital Deficit WorkingCapitalDeficit	-3256461	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zEImzqO6Y2U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zzsrUlA4zC4g">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	458839	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	301779	usd
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	157060	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	636054	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	222866	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024Q1	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022Q3	MSSA	Share Repurchase Program Excise Tax Percentage ShareRepurchaseProgramExciseTaxPercentage	0.01	pure
CY2023Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	2436497	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5915000	shares
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	301779	usd
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	157060	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	858920	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	636054	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	222866	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024Q1	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022Q3	MSSA	Share Repurchase Program Excise Tax Percentage ShareRepurchaseProgramExciseTaxPercentage	0.01	pure
CY2023Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	2436497	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5915000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	297020	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	595502	usd
CY2024Q1	MSSA	Remeasurement To Redemption Value RemeasurementToRedemptionValue	150000	usd
CY2023Q1	MSSA	Remeasurement To Redemption Value RemeasurementToRedemptionValue	757676	usd
CY2024Q1	MSSA	Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares	458839	usd
CY2023Q1	MSSA	Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares	858920	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-311819	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1021094	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	297020	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	595502	usd
CY2024Q1	MSSA	Remeasurement To Redemption Value RemeasurementToRedemptionValue	150000	usd
CY2023Q1	MSSA	Remeasurement To Redemption Value RemeasurementToRedemptionValue	757676	usd
CY2024Q1	MSSA	Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares	458839	usd
CY2023Q1	MSSA	Interest And Dividends Earned In Trust Account To Be Allocated To Redeemable Shares InterestAndDividendsEarnedInTrustAccountToBeAllocatedToRedeemableShares	858920	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-311819	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1021094	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zrfergYItAib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z2GMDUwbodG">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zrfergYItAib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z2GMDUwbodG">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5885324	shares
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50000	usd
CY2023Q4	us-gaap	Share Price SharePrice	0.033
CY2023Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2412260	shares
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50000	usd
CY2023Q4	us-gaap	Share Price SharePrice	0.033
CY2023Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2412260	shares
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	115000000	usd
CY2024Q1	MSSA	Proceeds Allocated To Public Rights ProceedsAllocatedToPublicRights	8510000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	5290000	usd
CY2024Q1	MSSA	Allocation Of Offering Costs Related To Ordinary Shares AllocationOfOfferingCostsRelatedToOrdinaryShares	5020172	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	86382792	usd
CY2024Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	21137903	usd
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	36017927	usd
CY2023Q1	MSSA	Payment Of Extesnsion Fee PaymentOfExtesnsionFee	383333	usd
CY2023Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.033
CY2023Q1	MSSA	Payment For Extension Fee PaymentForExtensionFee	187155	usd
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	5885324	shares
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.033
CY2023Q4	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	2412260	shares
CY2024Q1	MSSA	Deferred Underwriting Commission DeferredUnderwritingCommission	2875000	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	25000	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	150000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	115000000	usd
CY2024Q1	MSSA	Proceeds Allocated To Public Rights ProceedsAllocatedToPublicRights	8510000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	5290000	usd
CY2024Q1	MSSA	Allocation Of Offering Costs Related To Ordinary Shares AllocationOfOfferingCostsRelatedToOrdinaryShares	5020172	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	86382792	usd
CY2024Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	21137903	usd
CY2024Q1	MSSA	Subsequent Measurement Of Class Ordinary Shares Subject To Possible Redemption Interest Earned On Trust Account SubsequentMeasurementOfClassOrdinarySharesSubjectToPossibleRedemptionInterestEarnedOnTrustAccount	5082988	usd
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	36017927	usd
CY2023Q1	MSSA	Payment Of Extesnsion Fee PaymentOfExtesnsionFee	383333	usd
CY2023Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.033
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	5885324	shares
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.033
CY2023Q4	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	2412260	shares
CY2024Q1	MSSA	Deferred Underwriting Commission DeferredUnderwritingCommission	2875000	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	25000	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	150000	usd
CY2024Q1	MSSA	Monthly Payment Description MonthlyPaymentDescription	The Company entered into the agreement with a retainer of $5,000 per month starting from April 1, 2022
CY2024Q1	us-gaap	Legal Fees LegalFees	2500	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	15000	usd
CY2024Q1	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	245000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3205000	shares
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11500000	shares
CY2024Q1	MSSA	Monthly Payment Description MonthlyPaymentDescription	The Company entered into the agreement with a retainer of $5,000 per month starting from April 1, 2022
CY2024Q1	us-gaap	Legal Fees LegalFees	2500	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	15000	usd
CY2024Q1	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	245000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3205000	shares
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11500000	shares
CY2024Q3	us-gaap	Notes Payable NotesPayable	250000	usd
CY2024Q3	us-gaap	Notes Payable NotesPayable	250000	usd

Files In Submission

Name	View Source	Status
0001493152-24-036959-index-headers.html	Edgar Link	pending
0001493152-24-036959-index.html	Edgar Link	pending
0001493152-24-036959.txt	Edgar Link	pending
0001493152-24-036959-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mssa-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mssa-20240331_cal.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
mssa-20240331_def.xml	Edgar Link	unprocessable
mssa-20240331_pre.xml	Edgar Link	unprocessable
mssa-20240331_lab.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MSSA
Metal Sky Star Acquisition Corp Stock $mssa

2024 Q1 Form 10-Q Financial Statement

#000149315224036959 Filed on September 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MSSA Metal Sky Star Acquisition Corp Stock $mssa

2024 Q1 Form 10-Q Financial Statement

#000149315224036959 Filed on September 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MSSA
Metal Sky Star Acquisition Corp Stock $mssa